Literature DB >> 11556831

Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis.

M von Schlippe1, C J Fowler, S J Harland.   

Abstract

In order to ascertain the incidence and prognosis of cisplatin-induced neurotoxicity in testis cancer patients undergoing combination chemotherapy, 29 patients with metastatic disease were studied prospectively. Assessments included enquiry into neurological symptoms, measurement of sural nerve sensory action potential and conduction velocity, and vibration threshold in the left big toe. At the end of chemotherapy (3 to 4 cycles) only 3 out of 26 (11%) patients had paraesthesiae, but 3 months later the proportion rose to 65%. Resolution occurred in the majority over the ensuing 12 months so that only 17% had persistent symptoms. None of the 11 patients treated with 3 cycles of chemotherapy had persisting symptoms. Vibration thresholds showed a significant deterioration during chemotherapy (P = 0.032), further deterioration in the 3 months following chemotherapy (P = 0.009) and significant improvement between 3 and 12 months after chemotherapy (P = 0.038). Sural nerve sensory action potentials and conduction velocities were unhelpful. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11556831      PMCID: PMC2375074          DOI: 10.1054/bjoc.2001.2006

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Vibratory perception in normal subjects; a biothesiometric study.

Authors:  I STEINESS
Journal:  Acta Med Scand       Date:  1957-09-20

2.  Vibratory perception in diabetics; a biothesiometric study.

Authors:  I STEINESS
Journal:  Acta Med Scand       Date:  1957-09-20

3.  Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum(II) treatment: a case report.

Authors:  A Kedar; M E Cohen; A I Freeman
Journal:  Cancer Treat Rep       Date:  1978-05

4.  Quantitative evaluation of toxic neuropathies in man.

Authors:  P M Le Quesne; C J Fowler
Journal:  Electroencephalogr Clin Neurophysiol Suppl       Date:  1987

5.  Sensory nerve conduction in lower extremities.

Authors:  M DiBenedetto
Journal:  Arch Phys Med Rehabil       Date:  1970-05       Impact factor: 3.966

6.  Platinum nephrotoxicity.

Authors:  W T Hardaker; R A Stone; R McCoy
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

7.  The peripheral nerve function in chronic renal failure. IV. An analysis of the vibratory perception threshold.

Authors:  V K Nielsen
Journal:  Acta Med Scand       Date:  1972-04

8.  Chemotherapy of disseminated testicular cancer. A random prospective study.

Authors:  L H Einhorn; S D Williams
Journal:  Cancer       Date:  1980-09-15       Impact factor: 6.860

9.  cis-Platinum-induced hypomagnesemia and peripheral neuropathy.

Authors:  M Ashraf; P L Scotchel; J M Krall; E B Flink
Journal:  Gynecol Oncol       Date:  1983-12       Impact factor: 5.482

10.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

View more
  19 in total

1.  Evaluation of Cisplatin Neurotoxicity in Cultured Rat Dorsal Root Ganglia via Cytosolic Calcium Accumulation.

Authors:  Kevser Erol; Semra Yiğitaslan; Çiğdem Ünel; Bilgin Kaygısız; Engin Yıldırım
Journal:  Balkan Med J       Date:  2016-03-01       Impact factor: 2.021

Review 2.  Nanocarriers for delivery of platinum anticancer drugs.

Authors:  Hardeep S Oberoi; Natalia V Nukolova; Alexander V Kabanov; Tatiana K Bronich
Journal:  Adv Drug Deliv Rev       Date:  2013-10-08       Impact factor: 15.470

3.  [Side effects of tumor pharmacotherapy. What internists should know].

Authors:  E Wollmer; A Neubauer
Journal:  Internist (Berl)       Date:  2011-12       Impact factor: 0.743

4.  Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer.

Authors:  Óscar Arrieta; N Hernández-Pedro; M C Fernández-González-Aragón; D Saavedra-Pérez; A D Campos-Parra; M Á Ríos-Trejo; T Cerón-Lizárraga; L Martínez-Barrera; B Pineda; G Ordóñez; A Ortiz-Plata; V Granados-Soto; J Sotelo
Journal:  Neurology       Date:  2011-08-24       Impact factor: 9.910

5.  Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer.

Authors:  Mette Sprauten; Thomas H Darrah; Derick R Peterson; M Ellen Campbell; Robyn E Hannigan; Milada Cvancarova; Clair Beard; Hege S Haugnes; Sophie D Fosså; Jan Oldenburg; Lois B Travis
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

Review 6.  Chemotherapy-induced neuropathy.

Authors:  Anjali Bhagra; Ravi D Rao
Journal:  Curr Oncol Rep       Date:  2007-07       Impact factor: 5.075

Review 7.  Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.

Authors:  Lois B Travis; Sophie D Fossa; Howard D Sesso; Robert D Frisina; David N Herrmann; Clair J Beard; Darren R Feldman; Lance C Pagliaro; Robert C Miller; David J Vaughn; Lawrence H Einhorn; Nancy J Cox; M Eileen Dolan
Journal:  J Natl Cancer Inst       Date:  2014-03-12       Impact factor: 13.506

8.  Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors.

Authors:  Jan Oldenburg; Sophie D Fosså; Alv A Dahl
Journal:  Qual Life Res       Date:  2006-06       Impact factor: 3.440

9.  Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.

Authors:  Marianne Brydøy; Jan Oldenburg; Olbjørn Klepp; Roy M Bremnes; Erik A Wist; Tore Wentzel-Larsen; Erik R Hauge; Olav Dahl; Sophie D Fosså
Journal:  J Natl Cancer Inst       Date:  2009-12-16       Impact factor: 13.506

10.  Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF).

Authors:  Chunkit Fung; David J Vaughn; Nandita Mitra; Stephanie L Ciosek; Saran Vardhanabhuti; Katherine L Nathanson; Peter A Kanetsky
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-13       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.